News | April 01, 2026
Rusan unveils APOSAN 3ml multi-dose pen
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The decision is based on the phase 3 DESTINY-Breast11 trial
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Subscribe To Our Newsletter & Stay Updated
